Loading…
← CockpitCompetitor Analysis › 4588.T Oncolys BioPharma, Inc.Open in the cockpit ↗

Oncolys BioPharma, Inc.4588.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Biotechnology

Japanese biotech developing oncolytic virus therapies and antiviral drugs, notably Telomelysin for cancer.

≈ A small-cap Japanese oncolytic-virus biotech, akin to early ReplimuneMomentum leader 100
Mkt cap
$1.37B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$85.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.4%
Hurdle
n/a
no reverse DCF
Next earnings
79 days
5 Feb 2027
Close · JPY¥7,540
1D-1.1%
1W-4.6%
1M+46.1%
3M+132.0%
6M+181.3%
YTD+444.8%
1Y+885.6%
ATR %9.5%
52w lowhigh12.3% off high

What Oncolys BioPharma does

Japanese biotech developing oncolytic virus therapies and antiviral drugs, notably Telomelysin for cancer.

Depends on raising capital and licensing deals to fund trials. Oncolytic viruses are viruses engineered to infect and destroy cancer cells while sparing healthy tissue; Telomelysin uses a viral control element that switches on only in cells with an active telomerase, an enzyme most cancers use.

In one line: A small-cap Japanese oncolytic-virus biotech, akin to early Replimune.

Products and services

  • Telomelysin (oncolytic virus, cancer)
  • Antiviral drug candidates

Customers

  • Hospitals/cancer patients (post-approval)
  • Pharma licensing partners

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Oncolytic virus & antiviral drug…

What could go right

  • Positive clinical trial readouts
  • Licensing deals with larger pharma

What could go wrong

  • Clinical trial failure risk
  • Small-cap biotech funding/dilution risk

Moat: narrow (IP / patents). Proprietary oncolytic-virus technology platform, though still largely pre-commercial.

Headquarters: Tokyo, Japan · Founded: 2004 · Employees: 38

Named competitors

Oncolys BioPharma at a glance

Size Oncolys BioPharma (4588.T) is a Japan Health Care company (Biotechnology) with a market value of $1.37B, the 606th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥7,540 on 18 Nov 2026.

Performance Over six months the shares gained 181.3%, against -18.9% for the median peer and -1.4% for the Japan market (cap-weighted) — highest of 19 in its peer set.

Growth Revenue grew 1,749.0% over the last twelve months (peer median +24.8%); the operating margin is -295.1% (peer median -179.2%).

Valuation It trades at 408.9× enterprise value to sales against a peer median of 21.3× (2nd most expensive of 18).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 20264588.T 275Peer median 79
Six months, rebased to 100: Oncolys BioPharma against the median of its 20 peers (local-currency closes).

Oncolys BioPharma financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥528M¥28.5M¥31.4M¥63.0M¥976M
Revenue growth—-9%-50%-94%—
Gross profit¥527M¥28.3M¥30.6M¥30.6M¥338M
EBITDA-¥1.56B-¥2.02B-¥1.68B-¥1.93B-¥1.20B
Net income-¥1.56B-¥2.06B-¥1.68B-¥1.94B-¥1.15B
Free cash flown/a-¥1.94B-¥2.02B-¥1.34B-¥1.72B
Capital expendituren/a¥3.01M¥3.52M¥5.69M¥1.36M
Total debt¥232M¥320M¥325M¥315M¥394M

Quarterly statements and history in the cockpit →

Oncolys BioPharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%NTLA688185RAPPTYRAANABNUVBABSIQURE688105NVAX688765MSB0870104588.T6-month return →1-month return →
Up and to the right = strong over both horizons. Oncolys BioPharma is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×250×500×750×NTLA688185NUVBABSIQURE688806TSHA688765MSB0870104588.TRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Oncolys BioPharma is the large dot.

Oncolys BioPharma competitors and peer comparison

Head to head with its named competitors (4588.T vs REPL vs AMGN vs 4503.T)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Oncolys BioPharma 4588.T$1.37B+181%+1,749%-295%408.9×n/a
Replimune REPL$1.88B+321%n/an/an/an/a
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Astellas Pharma 4503.T$31.4B+17%+19%23%2.2×-9.0%

How Oncolys BioPharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Oncolys BioPharma against its 20 peers (data as of 18 Nov 2026)
Measure4588.TPeer medianRank in peer set
1-month return+46.1%-15.3%highest of 21
6-month return+181.3%-18.9%highest of 19
Distance from 52-week high-12.3%-47.0%highest of 21
Revenue growth (TTM)+1,749.0%+24.8%highest of 18
Operating margin-295.1%-179.2%10th highest of 19
EV / Sales408.9×21.3×2nd most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a

Questions

Who are Oncolys BioPharma's main competitors?
Named competitors: Replimune Group (REPL), Amgen (Imlygic) (AMGN), Astellas Pharma (4503.T). The cockpit's measured peer set (industry) also includes Intellia Therapeutics (NTLA), CanSino Biologics (688185.SS), Rapport Therapeutics (RAPP), Tyra Bioscience (TYRA), AnaptysBio (ANAB), Generate Biomedicines (GENB).
Is Oncolys BioPharma expensive compared with its peers?
On ev / sales it trades at 408.9× against a peer median of 21.3×, 2nd most expensive of 18 in its peer set.
How has Oncolys BioPharma stock performed?
Over six months to 18 Nov 2026 the shares returned +181.3% against -18.9% for the median peer; over one year +885.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.